Last $4.59 USD
Change Today +0.05 / 1.10%
Volume 2.0M
XOMA On Other Exchanges
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $9.57
52 Week Low
05/8/14 - $3.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

180 Employees
Last Reported Date: 11/6/14
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $489.3K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $417.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $391.4K
Chief Commercial Officer and Vice President
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2013.

xoma corp (XOMA) Key Developments

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 03:40 PM

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 03:40 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: John W. Varian, Chief Executive Officer, President and Director.

XOMA Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reconfirms Earnings Guidance for 2014

XOMA Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Total revenues for the third quarter were $5.1 million, down from $6.3 million reported for the same period last year and lower than the $7 million Street estimate. Loss from operations was $20,453,000, compared to $17,223,000 a year ago. Net loss before taxes was $14,399,000, compared to $29,639,000 a year ago. Net loss was $14,399,000 or $0.17 per diluted share, compared to $29,624,000 or $0.34 per diluted share a year ago. For the nine months, total revenue was $14,518,000, compared to $22,917,000 a year ago. Loss from operations was $62,705,000, compared to $42,626,000 a year ago. Net loss before taxes was $30,983,000, compared to $71,774,000 a year ago. Net loss was $30,983,000 or $0.55 per diluted share, compared to $71,759,000 or $0.85 per diluted share a year ago. The company reconfirmed its anticipated cash used in ongoing operating activities during 2014 will be approximately $55.0 - $60.0 million. The Company's principal expenditures are towards costs associated with its gevokizumab Phase 3 clinical programs: the EYEGUARD program and the pyoderma gangrenosum program. The guidance assumes license and contract-related revenue to be received prior to year-end. This guidance initially was provided on March 4, 2014.

XOMA Corporation Initiates Pivotal Phase 3 Gevokizumab Study in Patients with Pyoderma Gangrenosum

XOMA Corporation announced its pivotal phase 3 gevokizumab study in patients with active pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulcers caused by this rare and debilitating disease. The FDA granted orphan drug designation to gevokizumab for PG in February 2014. The phase 3 randomized, placebo-controlled study will enroll 58 patients with active PG to receive gevokizumab 60 mg or placebo dosed subcutaneously once monthly, in addition to their current treatment regimen of low-dose corticosteroids and/or immunosuppressants. The primary endpoint is complete closure of the PG target ulcer determined at Day 126 with confirmation a minimum of two weeks later at Day 140.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $4.59 USD +0.05

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €6.84 EUR +0.24
BioInvent International AB kr2.88 SEK +0.03
Dyax Corp $13.27 USD +0.05
Intrexon Corp $26.07 USD -0.07
MorphoSys AG €77.21 EUR +0.237
View Industry Companies

Industry Analysis


Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at